Clinical trial
Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia
NCT00084071 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00084071 |
|---|---|
| Title | Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia |
| Official title | Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) for the Treatment of Patients With Severe Community-Acquired Pneumonia |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pneumonia |
| Intervention type | Drug |
| Interventions | Tifacogin |
| Enrollment | 2,136 |
| Start date | May 1, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Jun 8, 2004 |
| Last update posted | Dec 19, 2020 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Chile, France, Germany, Malaysia, Netherlands, New Zealand, Peru and 6 more |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: